FDA grants Ranbaxy final approval for generic Biaxin

HARYANA, India The Food and Drug Administration has granted final approval to Ranbaxy to manufacture and market generic Biaxin (clarithromycin).

The oral suspension of Biaxin, available in a 125 mg/mL and 250 mg/mL is used for treatment of tonsillitis, community acquired pneumonia, uncomplicated skin and skin structure infections, and disseminated mycobacterial infections.

The drug had annual sales of $25.3 million during the 12-month period ending in June, according to IMS Health data.

Login or Register to post a comment.